C12N 2310/1241
Tetrahymena
C12N2310/1241 (Tetrahymena) appears on 66 US grants and 19 published applications in this corpus.
Search patents in C12N- Granted patents
- 66
- Published applications
- 19
- Assignees
- 26
- Inventors
- 76
- Latest grant
- 8 Dec 2020
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 13 | 0 |
| 1998 | 11 | 0 |
| 1999 | 9 | 0 |
| 2000 | 9 | 0 |
| 2001 | 1 | 0 |
| 2002 | 7 | 2 |
| 2003 | 2 | 4 |
| 2004 | 1 | 1 |
| 2005 | 2 | 1 |
| 2006 | 2 | 1 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 1 | 0 |
| 2019 | 0 | 0 |
| 2020 | 1 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 2 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for modulating ATRX-dependent gene repression8 Dec 2020US 10,858,650 B2The General Hospital Corporation
- Recombinant adenovirus with increased safety and anticancer activities, and use thereof18 Sep 2018US 10,077,430 B2National Cancer Center
- Alteration of sequence of a target molecule16 May 2006US 7,045,293 B2The Regents of the University of Colorado
- Synthesis, deprotection, analysis and purification of RNA and ribozymes9 May 2006US 7,041,817 B2Sirna Therapeutics, Inc.
- Alteration of sequence of a target molecule24 May 2005US 6,897,016 B1The Regents of the University of Colorado
- Self-amplifying non-coding rna for targeted gene knockdown13 Aug 2026US 2026/0234618 A1The Regents of the University of California
- Methods and compositions for barcoding nucleic acid libraries and cell populations7 Jul 2022US 2022/0213469 A1Massachusetts Institute of Technology
- System for genome editing30 Jun 2022US 2022/0204975 A1President and Fellows of Harvard College
- Methods for Modulating ATRX-Dependent Gene Repression23 Nov 2017US 2017/0335317 A1The General Hospital Corporation
- Recombinant adenovirus with increased safety and anticancer activities, and use thereof26 Nov 2015US 2015/0337270 A1National Cancer Center
Most cited
By later US patents
- 2'deoxy-2'-alkylnucleotide containing nucleic acid521US 5,627,053 ARibozyme Pharmaceuticals, Inc. · 1997
- RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods496US 4,987,071 AUniversity Patents, Inc. · 1991
- Multivalent and multispecific binding proteins, their manufacture and use314US 5,837,242 ACambridge Antibody Technology Limited · 1998
- RNA ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods219US 5,093,246 AUniversity Patents, Inc. · 1992
- RNA ribozyme restriction endoribonucleases and methods164US 5,116,742 AUniversity Patents, Inc. · 1992